170 related articles for article (PubMed ID: 14529384)
21. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin.
Schulte TW; Akinaga S; Soga S; Sullivan W; Stensgard B; Toft D; Neckers LM
Cell Stress Chaperones; 1998 Jun; 3(2):100-8. PubMed ID: 9672245
[TBL] [Abstract][Full Text] [Related]
22. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.
Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H
J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586
[TBL] [Abstract][Full Text] [Related]
23. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents.
Bagatell R; Paine-Murrieta GD; Taylor CW; Pulcini EJ; Akinaga S; Benjamin IJ; Whitesell L
Clin Cancer Res; 2000 Aug; 6(8):3312-8. PubMed ID: 10955818
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.
Whitesell L; Mimnaugh EG; De Costa B; Myers CE; Neckers LM
Proc Natl Acad Sci U S A; 1994 Aug; 91(18):8324-8. PubMed ID: 8078881
[TBL] [Abstract][Full Text] [Related]
25. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site.
Hadden MK; Lubbers DJ; Blagg BS
Curr Top Med Chem; 2006; 6(11):1173-82. PubMed ID: 16842154
[TBL] [Abstract][Full Text] [Related]
26. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
Kelland LR; Sharp SY; Rogers PM; Myers TG; Workman P
J Natl Cancer Inst; 1999 Nov; 91(22):1940-9. PubMed ID: 10564678
[TBL] [Abstract][Full Text] [Related]
27. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.
Zhang H; Yang YC; Zhang L; Fan J; Chung D; Choi D; Grecko R; Timony G; Karjian P; Boehm M; Burrows F
Int J Cancer; 2007 Feb; 120(4):918-26. PubMed ID: 17131314
[TBL] [Abstract][Full Text] [Related]
28. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins.
Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
Mol Pharmacol; 2006 Oct; 70(4):1194-203. PubMed ID: 16825487
[TBL] [Abstract][Full Text] [Related]
29. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
[TBL] [Abstract][Full Text] [Related]
30. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
31. Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.
Hardcastle A; Boxall K; Richards J; Tomlin P; Sharp S; Clarke P; Workman P; Aherne W
Assay Drug Dev Technol; 2005 Jun; 3(3):273-85. PubMed ID: 15971989
[TBL] [Abstract][Full Text] [Related]
32. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors.
Minami Y; Kiyoi H; Yamamoto Y; Yamamoto K; Ueda R; Saito H; Naoe T
Leukemia; 2002 Aug; 16(8):1535-40. PubMed ID: 12145695
[TBL] [Abstract][Full Text] [Related]
33. Yeast is selectively hypersensitised to heat shock protein 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90beta, a property that can be exploited in screens for new Hsp90 chaperone inhibitors.
Piper PW; Panaretou B; Millson SH; Truman A; Mollapour M; Pearl LH; Prodromou C
Gene; 2003 Jan; 302(1-2):165-70. PubMed ID: 12527207
[TBL] [Abstract][Full Text] [Related]
34. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity.
Neckers L; Schulte TW; Mimnaugh E
Invest New Drugs; 1999; 17(4):361-73. PubMed ID: 10759403
[TBL] [Abstract][Full Text] [Related]
35. Learning from nature: advances in geldanamycin- and radicicol-based inhibitors of Hsp90.
Kitson RR; Moody CJ
J Org Chem; 2013 Jun; 78(11):5117-41. PubMed ID: 23496136
[TBL] [Abstract][Full Text] [Related]
36. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy.
Naoe T; Kiyoe H; Yamamoto Y; Minami Y; Yamamoto K; Ueda R; Saito H
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S27-30. PubMed ID: 11587362
[TBL] [Abstract][Full Text] [Related]
37. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.
Soga S; Neckers LM; Schulte TW; Shiotsu Y; Akasaka K; Narumi H; Agatsuma T; Ikuina Y; Murakata C; Tamaoki T; Akinaga S
Cancer Res; 1999 Jun; 59(12):2931-8. PubMed ID: 10383157
[TBL] [Abstract][Full Text] [Related]
38. Biotinylated geldanamycin.
Clevenger RC; Raibel JM; Peck AM; Blagg BS
J Org Chem; 2004 Jun; 69(13):4375-80. PubMed ID: 15202892
[TBL] [Abstract][Full Text] [Related]
39. Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases.
Sakagami M; Morrison P; Welch WJ
Cell Stress Chaperones; 1999 Mar; 4(1):19-28. PubMed ID: 10467105
[TBL] [Abstract][Full Text] [Related]
40. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors.
Ibrahim NO; Hahn T; Franke C; Stiehl DP; Wirthner R; Wenger RH; Katschinski DM
Cancer Res; 2005 Dec; 65(23):11094-100. PubMed ID: 16322259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
